These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38725258)

  • 1. Assessment of swallowability and acceptability of scored darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed-dose combination (FDC) tablets in HIV-1-infected children aged ≥6 to <12 years, using matching placebo tablets: A randomized study.
    Van Hemelryck S; Van Landuyt E; Hufkens V; Vanveggel S
    Antivir Ther; 2024 Apr; 29(2):13596535241248282. PubMed ID: 38725258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Week 96 resistance analyses of the once-daily, single-tablet regimen (STR) darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in adults living with HIV-1 from the phase 3 randomized AMBER and EMERALD trials.
    Lathouwers E; Weinsteiger S; Baugh B; Ghys A; Jezorwski J; Mohsine EG; Van Landuyt E; De Meyer S
    J Med Virol; 2021 Jun; 93(6):3985-3990. PubMed ID: 33300183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1.
    Eron JJ; Orkin C; Cunningham D; Pulido F; Post FA; De Wit S; Lathouwers E; Hufkens V; Jezorwski J; Petrovic R; Brown K; Van Landuyt E; Opsomer M;
    Antiviral Res; 2019 Oct; 170():104543. PubMed ID: 31279073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials.
    Lathouwers E; Wong EY; Brown K; Baugh B; Ghys A; Jezorwski J; Mohsine EG; Van Landuyt E; Opsomer M; De Meyer S;
    AIDS Res Hum Retroviruses; 2020 Jan; 36(1):48-57. PubMed ID: 31516033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population Pharmacokinetic Analysis of Darunavir and Tenofovir Alafenamide in HIV-1-Infected Patients on the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen (AMBER and EMERALD Studies).
    Ackaert O; McDougall D; Pérez-Ruixo C; Pérez-Ruixo JJ; Jezorwski J; Crauwels HM
    AAPS J; 2021 Jun; 23(4):82. PubMed ID: 34100149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study.
    Huhn GD; Eron JJ; Girard PM; Orkin C; Molina JM; DeJesus E; Petrovic R; Luo D; Van Landuyt E; Lathouwers E; Nettles RE; Brown K; Wong EY
    AIDS Res Ther; 2019 Aug; 16(1):23. PubMed ID: 31464642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioequivalence of a Pediatric Fixed-Dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Compared With Coadministration of the Separate Agents in Healthy Adults: An Open-Label, Randomized, Replicate Crossover Study.
    Van Hemelryck S; Van Landuyt E; Ariyawansa J; Vanveggel S; Palmer M
    Clin Pharmacol Drug Dev; 2023 Nov; 12(11):1060-1068. PubMed ID: 37335552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve patients with HIV-1: subgroup analyses of the phase 3 AMBER study.
    Rashbaum B; Spinner CD; McDonald C; Mussini C; Jezorwski J; Luo D; Van Landuyt E; Brown K; Wong EY
    HIV Res Clin Pract; 2019 Feb; 20(1):24-33. PubMed ID: 31303147
    [No Abstract]   [Full Text] [Related]  

  • 9. Fixed dose darunavir boosted with cobicistat combined with emtricitabine and tenofovir alafenamide fumarate.
    Cevik M; Orkin C
    Curr Opin HIV AIDS; 2018 Jul; 13(4):315-319. PubMed ID: 29528852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients.
    Orkin C; Eron JJ; Rockstroh J; Podzamczer D; Esser S; Vandekerckhove L; Van Landuyt E; Lathouwers E; Hufkens V; Jezorwski J; Opsomer M;
    AIDS; 2020 Apr; 34(5):707-718. PubMed ID: 31833849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Splitting or Crushing on the Relative Bioavailability of the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen.
    Brown K; Thomas D; McKenney K; Reeder M; Simonson RB; Bicer C; Nettles RE; Crauwels H
    Clin Pharmacol Drug Dev; 2019 May; 8(4):541-548. PubMed ID: 30508308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioequivalence of the Once-Daily Single-Tablet Regimen of Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Compared to Combined Intake of the Separate Agents and the Effect of Food on Bioavailability.
    Crauwels HM; Baugh B; Van Landuyt E; Vanveggel S; Hijzen A; Opsomer M
    Clin Pharmacol Drug Dev; 2019 May; 8(4):480-491. PubMed ID: 30412360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.
    Gaur AH; Kizito H; Prasitsueubsai W; Rakhmanina N; Rassool M; Chakraborty R; Batra J; Kosalaraksa P; Luesomboon W; Porter D; Shao Y; Myers M; Ting L; SenGupta D; Quirk E; Rhee MS
    Lancet HIV; 2016 Dec; 3(12):e561-e568. PubMed ID: 27765666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice.
    Ranzenigo M; Gianotti N; Galli L; Poli A; Mastrangelo A; Bruzzesi E; Chiurlo M; Nozza S; Bossolasco S; Spagnuolo V; Mancusi D; Termini R; Carini E; Lazzarin A; Castagna A
    Drug Des Devel Ther; 2022; 16():1975-1982. PubMed ID: 35783200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)-naïve and -experienced, virologically-suppressed adults living with HIV-1.
    Huhn GD; Wilkin A; Mussini C; Spinner CD; Jezorwski J; El Ghazi M; Van Landuyt E; Lathouwers E; Brown K; Baugh B;
    HIV Res Clin Pract; 2020 Dec; 21(6):151-167. PubMed ID: 33528318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide in the treatment of HIV-1.
    Negredo E; Clotet B
    Expert Opin Pharmacother; 2018 Jun; 19(8):929-934. PubMed ID: 29767543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial.
    Orkin C; Molina JM; Negredo E; Arribas JR; Gathe J; Eron JJ; Van Landuyt E; Lathouwers E; Hufkens V; Petrovic R; Vanveggel S; Opsomer M;
    Lancet HIV; 2018 Jan; 5(1):e23-e34. PubMed ID: 28993180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomised control trial of BIC/F/TAF vs DRV/c/F/TAF in context of HIV test-and-treat, BicTnT.
    Whitlock G; Fidler S; Clarke A; Kang S; Xhikola A; Milinkovic A; Soler-Carracedo A; Henderson M; Adams T; Jahan I; Khawaja A; Taylor G; Boffito M
    HIV Res Clin Pract; 2024 Dec; 25(1):2400453. PubMed ID: 39244669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide in the United States.
    Emond B; Rossi C; Côté-Sergent A; Bookhart B; Anderson D; Lefebvre P; Lafeuille MH; Donga P
    Curr Med Res Opin; 2022 Feb; 38(2):287-298. PubMed ID: 34812097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial.
    Kityo C; Hagins D; Koenig E; Avihingsanon A; Chetchotisakd P; Supparatpinyo K; Gankina N; Pokrovsky V; Voronin E; Stephens JL; DeJesus E; Wang H; Acosta RK; Cao H; Quirk E; Martin H; Makadzange T
    J Acquir Immune Defic Syndr; 2019 Nov; 82(3):321-328. PubMed ID: 31609930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.